Mouse monoclonal antibody against human CD41 / integrin aIIb (platelet glycoprotein IIb, part of the GPIIb/IIIa complex), clone VM16a, IgG1?, 0.2 mg. Recognises the intact platelet GPIIb/IIIa (aIIbß3) complex and does not bind dissociated GPIIb or GPIIIa, Glanzmann-thrombasthenia platelets or the vitronectin receptor. A platelet and megakaryocyte identification marker; pairs with the ß3 partner cat. 879 (mouse anti-CD61 / GPIIIa, clone CRC54) and the complex-specific cat. 751 (mouse anti-aIIbß3 complex, clone CRC64) for platelet-integrin work.
SPECIFICATIONS
Catalogue number: 424 | Host: Mouse | Target: Human
Target antigen: Human CD41 / integrin aIIb (platelet glycoprotein IIb); intact GPIIb/IIIa (aIIbß3) complex
Gene: ITGA2B (17q21.31) | UniProt: P08514
Clonality: Monoclonal | Clone: VM16a | Isotype: IgG1 kappa | Conjugate: Unconjugated
Specificity: Binds the intact platelet GPIIb/IIIa (aIIbß3) complex; no reactivity to dissociated GPIIb or GPIIIa, Glanzmann-thrombasthenia platelets, or the vitronectin receptor.
Purification: PEG 6000 precipitation and DEAE-cellulose anion-exchange chromatography with gradient elution
Format: Lyophilised; contains mannitol, dextran and salts | Package size: 0.2 mg (reconstitute to 1 mL)
STORAGE / RECONSTITUTION
Reconstitute with 1 mL sterile pure water. Ships at ambient temperature. Store lyophilised antibody 2 years at -20 °C or lower; store reconstituted antibody at +4 °C for up to 4 weeks, or aliquot and freeze. Avoid repeated freeze-thaw.
APPLICATIONS
- Flow cytometry — identification and characterisation of platelets and megakaryocytes by GPIIb/IIIa expression.
- Immunohistochemistry — detection of CD41 / GPIIb-expressing cells in tissue.
- Immunoprecipitation — isolation of the GPIIb/IIIa complex and its binding partners.
- Cell-adhesion studies — analysis of platelet integrin-mediated cell—cell and cell—matrix interactions.
APPLICATION HIGHLIGHTS — HIGH-VALUE RESEARCH NICHES
- Platelet & megakaryocyte identification — lineage marker in haematology and flow cytometry.
- Thrombosis & haemostasis — GPIIb/IIIa is the final common pathway of platelet aggregation.
- Glanzmann thrombasthenia — complex-dependent binding distinguishes normal from aIIbß3-deficient platelets.
- Anti-platelet drug development — GPIIb/IIIa is the target of aggregation-inhibitor therapeutics.
- Platelet disorders — marker in thrombocytopenia, leukaemia and megakaryopoiesis studies.
